LL-37
Also known as Human cathelicidin peptide · CAMP
Human antimicrobial peptide with topical wound healing studies. Antimicrobial therapeutic claims trigger regulatory scrutiny.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence visual
LL-37 evidence and risk matrix
intermediate researcher fit
Evidence
Tier B-C
Risk
high
Regulatory
not approved
WADA
none
FDA
unknown
Route
topical
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
LL-37 is a human cathelicidin peptide with antimicrobial and immunomodulatory properties. Human topical studies in chronic leg ulcers report safety/tolerability and effects on healing predictors at lower doses. Topical use appears tolerable in trials; systemic use is a different risk profile. Marketing with antimicrobial therapeutic claims triggers high regulatory scrutiny.
Decision path
Where LL-37 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether LL-37 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Antimicrobial and immunomodulatory; host defense and inflammation modulation.
topical
Human topical studies in wound healing contexts.
Wound healing support; antimicrobial properties in topical application.
Wound endpoints measured over weeks.
No formal label.
Topical appears tolerable; systemic use carries different risk profile.
Unknown.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for LL-37.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.